Table 1. Demographic and clinical characteristics of the 156 patients included in the study (4 LTP with decreased over time LSM were excluded). LSM, liver stiffness measurement; SOT-LSM, stable over time LSM; IOT-LSM, increased over time LSM; LT, liver transplantation; LTP, liver transplanted patients; BMI, body mass index; ALT, alanine aminotransferase.

	Stable SOT-LSM Group (n = 121)	Progressive IOT-LSM Group (n = 35)	P Value
Clinical parameters
Gender, male, n (%)	96 (79.3)	24 (68.6)	0.18
Age at LT, years median (range)	53 (18 - 67)	56 (30 - 66)	0.15
Age at first LSM, median (range)	60 (27 - 75)	62 (39 - 70)	0.86
Months after LT at baseline LSM, median (range)	60 (2 - 252)	60 (2 - 228)	0.44
Transplant for HBV disease, n (%)	60 (49.6)	6 (17.1)	< 0.001
Transplant for HCV disease, n (%)	41 (33.9)	28 (80.0)	< 0.0001
Transplant for other liver diseases, n (%)	20 (16.5)	1 (3.0)	0.17
Cyclosporine-based immunosuppression, n (%)	35 (28.9)	17 (48.6)	0.03
Tacrolimus-based immunosuppression, n %)	70 (57.8)	17 (48.6)	0.33
Other immunosuppressants, n (%)	16 (13.2)	1 (2.8)	0.08
HCV-RNA positive at baseline LSM, n (%)	28 (23.1)	25 (71.4)	< 0.0001
Elevated ALT levels, n (%)	19 (15.7)	21 (60)	< 0.0001
Comorbidities
Diabetes, n (%)	28 (23.1)	8 (22.8)	0.97
Hypertension, n (%)	73 (60.3)	18 (51.4)	0.35
Chronic renal failure, n (%)	38 (31.4)	11 (31.4)	0.99
Overweight, BMI (Kg/m2) > 25 < 30, n (%)	87 (71.9)	23 (65.7)	0.48
Obese, BMI (Kg/m2) >30, n (%)	22 (18.2)	4 (11.4)	0.34
Biliary complications after LT, n (%)	22 (18.2)	14 (40.0)	0.007
Liver stiffness measurement (LSM)
LSM at first observation, kPa median (range)	5.4 (3.1 - 35.3)	9.3 (4.8 - 32.0)	< 0.0001
LSM at last observation, kPa median (range)	5.3 (3 - 34.8)	20.4 (8.3 - 75)	< 0.0001
Observed clinical events	2 (1.6)	24 (68)	< 0.0001
Newly defined cirrhosis, n (%)	0	16 (46)	< 0.0001
Clinical decompensation, n (%)	2 (1.6)	16 (46)	< 0.0001
Liver-related deaths, n (%)	1 (0.8)	6 (17)	0.001
Total deaths, n (%)	3 (2.4)	6 (17)	0.004